Comparison
Bromantane vs Epitalon
Side-by-side of Bromantane and Epitalon. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Bromantane
Bromantane, the Russian nootropic sold as Ladasten (ADK-709), acts on dopamine to cut fatigue and anxiety without classical stimulant rebound.
Epitalon
Epitalon peptide (Epithalon, tetrapeptide AEDG): telomerase activation, lifespan extension data, anti-aging trials, dosage, half-life, and safety.
Effects at a glance
Bromantane
- •Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
- •Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
- •Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
- •Long half-life of around 11 hours supports once-daily morning dosing
- •WADA-banned since 1996; relevant for tested athletes
- •Western evidence base is thin; most published trials are Russian-language and not independently replicated
Epitalon
- •Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed at the St. Petersburg Institute of Bioregulation
- •Russian clinical literature reports mortality reduction in elderly cohorts and improved melatonin output
- •Reported telomerase activation in human somatic cell culture and lifespan extension in mice and Drosophila
- •Independent Western replication is essentially absent; no FDA-standard RCTs
- •Anecdotal protocols use 5 to 10 mg subcutaneously daily for 10 to 20 day cycles, 2 to 4 times yearly
- •Not currently on the WADA Prohibited List
Side-by-side
| Attribute | Bromantane | Epitalon |
|---|---|---|
| Category | nootropic | peptide |
| Also known as | Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine | Epithalon, Ala-Glu-Asp-Gly, AEDG, Epithalamin (precursor extract) |
| Half-life (hr) ↗ | 11 | 0.5 |
| Typical dose (mg) ↗ | 75 | 5 |
| Dosing frequency | daily, morning | daily during cycle |
| Routes | oral | subcutaneous, intramuscular, intranasal |
| Onset (hr) | 3 | 24 |
| Peak (hr) | 168 | 168 |
| Molecular weight | 280.21 | 390.35 |
| Molecular formula | C16H20BrN | C14H22N4O9 |
| Mechanism | Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. | Synthetic tetrapeptide proposed to interact directly with DNA and chromatin to modulate tissue-specific gene expression. Reported effects include telomerase activation, increased melatonin output from pineal cells, and circadian normalization. |
| Legal status | Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK | Not FDA approved; registered in Russia under domestic pharmaceutical framework; research-use-only grey market in US/EU |
| WADA status | banned | unknown |
| DEA / Rx | Not scheduled in the US | Not scheduled (research chemical) |
| Pregnancy | Not recommended | Insufficient data; not recommended |
| CAS | 87913-26-6 | 307297-39-8 |
| PubChem CID | 9576456 | 219042 |
| Wikidata | Q4093816 | Q5384126 |
Safety profile
Bromantane
Common side effects
- mild GI upset
- headache
- skin rash
- occasional insomnia at higher doses
Contraindications
- pregnancy
- lactation
- severe hepatic impairment
- severe renal impairment
- pediatric use
Interactions
- MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
- levodopa and dopamine agonists: additive dopaminergic activity(moderate)
- SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
- classical stimulants: theoretical additive activity, undocumented(moderate)
Epitalon
Common side effects
- injection-site reactions
- occasional mild headache (rare)
Contraindications
- pregnancy
- lactation
- active malignancy (theoretical telomerase concern)
- concurrent immunosuppression
Interactions
- melatonin: potential additive effect on circadian and pineal output; no controlled data(minor)
Which Should You Take?
Bromantane comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-C outcome catalogued. Epitalon is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Bromantane.
- → If your priority is fatigue resistance, pick Bromantane.
- → If your priority is healthspan extension, pick Epitalon.
- → If your priority is sleep onset or sleep quality, pick Epitalon.
Edge case: If you cannot self-administer injections, Bromantane is the only oral option in this pair.
Default choice: Bromantane. Wider use case, and broader goal coverage. Reach for Epitalon only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Bromantane and Epitalon?
Bromantane and Epitalon differ in category (nootropic vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Bromantane or Epitalon?
Bromantane half-life is 11 hours; Epitalon half-life is 0.5 hours.
Can you stack Bromantane with Epitalon?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper